Kymera IPO Presentation Deck

IL-1R / TLR JAK / STAT Internal Sanofi-partnered" Program KYMERA IRAK4* IRAKIMID (IRAK4, Ikaros, Aiolos) STAT3 Various Undisclosed Vertex-partnered Undisclosed Indication HS, AD, RA MYD88MT DLBCL Liquid and Solid Tumors Upcoming Catalysts H1 Phase 1 Start 2021 POB Phase 1 Start Phase 1 Start HI Phase 2 Start POB POB 2022 H₂ POC Immunology-inflammation POC *Kymera will have the option to participate in the development and commercialization of Sanofi-partnered programs in the US during clinical development Multiple degrader programs in immune-inflammatory and genetically defined oncology indications with DC/IND nominations in this timeframe Oncology Research and development of degraders against an undisclosed target Research and development of degraders against up to 6 targets in disease areas outside of our core strategic focus of immunology-inflammation and oncology

View entire presentation